![Genetic polymorphism in ATIC is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer | Thorax Genetic polymorphism in ATIC is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer | Thorax](https://thorax.bmj.com/content/thoraxjnl/76/11/1150/F1.large.jpg)
Genetic polymorphism in ATIC is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer | Thorax
![PDF) The Role of Pemetrexed in Advanced Non Small-Cell Lung Cancer: Special Focus on Pharmacology and Mechanism of Action PDF) The Role of Pemetrexed in Advanced Non Small-Cell Lung Cancer: Special Focus on Pharmacology and Mechanism of Action](https://www.researchgate.net/profile/Thomas-Cerny-2/publication/38021052/figure/fig1/AS:601666906755090@1520459977958/figure-fig1_Q320.jpg)
PDF) The Role of Pemetrexed in Advanced Non Small-Cell Lung Cancer: Special Focus on Pharmacology and Mechanism of Action
![Associations between TS, TTF-1, FR-α, FPGS, and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin or Gemcitabine Plus Carboplatin as First-Line Chemotherapy - Journal of Thoracic Oncology Associations between TS, TTF-1, FR-α, FPGS, and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin or Gemcitabine Plus Carboplatin as First-Line Chemotherapy - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2040329455/2053819740/gr1.jpg)
Associations between TS, TTF-1, FR-α, FPGS, and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin or Gemcitabine Plus Carboplatin as First-Line Chemotherapy - Journal of Thoracic Oncology
![Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma: Trends in Pharmacological Sciences Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma: Trends in Pharmacological Sciences](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/354c6842-b971-4442-bf7b-f264f6f89467/gr3.jpg)
Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma: Trends in Pharmacological Sciences
![PPT - First-Line Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) PowerPoint Presentation - ID:4546594 PPT - First-Line Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) PowerPoint Presentation - ID:4546594](https://image2.slideserve.com/4546594/pemetrexed-key-intracellular-folate-enzyme-targets-l.jpg)
PPT - First-Line Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) PowerPoint Presentation - ID:4546594
![Molecules | Free Full-Text | Novel Multitarget Therapies for Lung Cancer and Respiratory Disease | HTML Molecules | Free Full-Text | Novel Multitarget Therapies for Lung Cancer and Respiratory Disease | HTML](https://www.mdpi.com/molecules/molecules-25-03987/article_deploy/html/images/molecules-25-03987-g001-550.jpg)
Molecules | Free Full-Text | Novel Multitarget Therapies for Lung Cancer and Respiratory Disease | HTML
![Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients | Pharmacogenomics Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients | Pharmacogenomics](https://www.futuremedicine.com/cms/10.2217/pgs.15.14/asset/images/medium/figure1.gif)
Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients | Pharmacogenomics
![Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape - Annals of Oncology Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/1e2be9d3-e5ef-46f8-a456-70c984acd1c0/gr1_lrg.jpg)
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape - Annals of Oncology
![Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy | Journal for ImmunoTherapy of Cancer Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/8/2/e001392/F6.large.jpg?width=800&height=600&carousel=1)
Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy | Journal for ImmunoTherapy of Cancer
![Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural Mesothelioma - Journal of Thoracic Oncology Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural Mesothelioma - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2040234497/2053760923/gr1.jpg)
Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural Mesothelioma - Journal of Thoracic Oncology
![Illustration of the similarities and differences between the cellular... | Download Scientific Diagram Illustration of the similarities and differences between the cellular... | Download Scientific Diagram](https://www.researchgate.net/profile/Alex-Adjei/publication/6978153/figure/fig2/AS:601677249929259@1520462443997/Illustration-of-the-similarities-and-differences-between-the-cellular-mechanism-of-action.png)
Illustration of the similarities and differences between the cellular... | Download Scientific Diagram
![Frontiers | Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting? | Oncology Frontiers | Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting? | Oncology](https://www.frontiersin.org/files/Articles/367657/fonc-08-00267-HTML/image_m/fonc-08-00267-g001.jpg)
Frontiers | Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting? | Oncology
![Lung-Tumorzym (LT-Zym) plus Pemetrexed (Alimta) deliver combo punch to terminal non–small cell lung cancer (NSCLC) | Herbalzym Lung-Tumorzym (LT-Zym) plus Pemetrexed (Alimta) deliver combo punch to terminal non–small cell lung cancer (NSCLC) | Herbalzym](http://www.herbalzym.com/wp-content/uploads/2010/10/pemetrexed-mechanism-of-action.png)
Lung-Tumorzym (LT-Zym) plus Pemetrexed (Alimta) deliver combo punch to terminal non–small cell lung cancer (NSCLC) | Herbalzym
![Mechanisms of resistance to pemetrexed in non-small cell lung cancer - Liang - Translational Lung Cancer Research Mechanisms of resistance to pemetrexed in non-small cell lung cancer - Liang - Translational Lung Cancer Research](https://cdn.amegroups.cn/journals/pbpc/files/journals/5/articles/33248/public/33248-PB4-6905-R1.png/w300)
Mechanisms of resistance to pemetrexed in non-small cell lung cancer - Liang - Translational Lung Cancer Research
![Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules | British Journal of Cancer Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsj.bjc.6603995/MediaObjects/41416_2007_Article_BF6603995_Fig1_HTML.gif)
Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules | British Journal of Cancer
![High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase](https://www.spandidos-publications.com/article_images/or/38/5/OR-38-05-2787-g05.jpg)